Background
Vaccine adjuvants enhance humoral and cellular responses but may induce reactogenicity. AS01B, MF59, and Alum have distinct mechanisms, yet head-to-head comparisons of immunogenicity and reactogenicity are scarce.
Methods
We conducted a cross-protocol, post-hoc, analysis of four randomized, controlled, double-blind trials (HVTN 100, 107, 120, and 702) of adults without HIV who received ALVAC-HIV (vCP2438) vaccine and a bivalent gp120 protein booster with MF59, Alum, or AS01B. ALVAC-HIV was administered at months 0, 1, 3, 6 and the booster at months 3, 6. Month 6.5 samples were analyzed for IgG/IgG3 V1V2 via binding antibody multiplex assay (BAMA) and CD4+ T-cell responses via intracellular cytokine staining (ICS). Reactogenicity was recorded via diaries and case report forms. Response rates were compared using Barnard’s test and magnitudes using Wilcoxon. False discovery rate adjusted p-values are reported.
Results
Immunogenicity data were available for 320 (MF59), 27 (Alum), and 46 (AS01B) vaccine recipients. Demographic for immune data were similar across groups (median age: 24; 56.5% female), most were from South Africa (70.5%). Among responders,AS01B elicited higher IgG magnitudes than MF59 and Alum for the vaccine-matched 1086C V1V2 and Con 6 gp120 consensus antigens (all p<0.001). AS01B also induced greater IgG responses than MF59 for vaccine-matched ZM96 V1V2 (p<0.001) and B.CaseA_V1_V2, identified as a correlate in RV144 (p= 0.026).Positive CD4+ T cell responses (IFN-γ and/or IL-2 expression) to each of the 3 vaccine-matched antigens were frequent among AS01B recipients. For ZM96, 88% for AS01B vs. 63% for MF59 (p=0.032) and 55% for Alum (p=0.006). For 1086, the responses were 90% vs. 47% (p<0.001) and 63% (p=0.018). For TV1, the responses were 95% vs. 71% (p<0.001) and 63% (p=0.018). Among responders, CD4+ T cell responses to 1086 gp120, TV1 gp120, and ZM96 were also higher with AS01B (all p<0.05). Reactogenicity data from 3086 participants showed systemic symptoms including fatigue, myalgia, headache, arthralgia, and chills Although no formal correlations were conducted, symptoms were generally more frequent with AS01B, intermediate with MF59, and lowest with Alum with most events reported as mild.
Conclusions
All vaccines presented an acceptable safety profile. In this post-hoc analysis, the AS01B adjuvanted vaccine demonstrated superior immunogenicity, eliciting higher magnitudes for both IgG and CD4+ T-cell responses compared to MF59 and Alum-adjuvanted formulations.